NDAINTRAVENOUSINJECTABLE
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C;…
Indications (1)
Clinical Trials (2)
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Started Nov 2010
9 enrolled
Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Started Sep 2003
24 enrolled
ThrombocytopeniaThrombosis